FOR PATIENTS
— efficient and safe
— both in hospitals and at home
— prevention of hospitalization
— faster recovery
— reduced contagiosity and isolated period
— convenient per os
FOR DOCTORS
— no fear of COVID-19
— decreased burden on hospitals by 3 times
— reduced hospitalization period by 30
FOR ECONOMY
— reduced social tensions
— reduced disability period
— support of economy
— prevention of lockdown
About us
Avifavir® is the first effective drug for COVID‐19 treatment registered in Russia
The founder of our EFCI fund is European Medical Alliance LLC (EurMA), which is the authorized representative of the Russian pharmaceutical company Chromis LLC, a joint venture (JV) of the Russian Direct Investment Fund (RDIF), the Russian
State Wealth Fund, with the ChemRar Group, aimed at the production of Avifavir® and other related innovative antiviral drugs. Together with our founders, we represent interests in the regions of Europe, Latin America, Asia and Africa.
OUR DEVELOPMENT
Avifavir® status by today
A short history of the development of Avifavir® in the period 2020-2021. Today Avifavir® is registered in 15 countries. The situation changes daily. Avifavir® has entered the international market and our Foundation is taking part in
this.
AVIFAVIR® ADVANTAGES
Fully developed and scaled technology of API and DP manufacturing
— High quality of the product: 2 years stability
— Proprietary IP
— Clinical results efficacy in COVID-19 treatment 460 patients in 35 medical centers of Russia took part in clinical trials (phase II / III) of Avifavir®
— Fast supply of drug products to any destination 600 000+ packs per month manufacturing at 3 sites in Russia
— Option for technology transfer to local partner for a long-term collaboration
— Competitive pricing
Our mission
Promotes a progressive medicine that can stop the pandemic and help ordinary people overcome the disease.
Experts’ opinions
The drug proved to be highly effective during the clinical trials involving I.M. Sechenov First Moscow State Medical University, Lomonosov Moscow State University and other medical and academic institutions.
Avifavir was first developed and licensed as commercial drug by ChemRar Group with the support of the Russian Direct Investment Fund and the Ministry of Industry and Trade of Russia. The permanent Marketing Authorization was obtained
based on the clinical trial data covering 460 patients, which proved the drug’s ability to block the replication mechanisms of coronavirus, alleviate symptoms and reduce the duration of the disease by half compared to the conventional
therapy. This clinical trial has been conducted in 35 medical centers across Russia.
Avifavir is one of the two registered drugs against coronavirus in the world. It is also the first drug against coronavirus registered in Russia, having demonstrated efficacy in clinical trials. Its inclusion in the guidelines
for the prevention, diagnosis and treatment of coronavirus will allow patients across the country to receive therapy using the most effective drug currently available in Russia, as well as preventing the Russian healthcare
system from being overwhelmed by the reduction in recovery time.
Kirill Dmitriev
Chromis, the joint venture established by RDIF and ChemRar Group, along with all other citizens of the Russian Federation, received a welcome present for National Unity Day – a permanent registration for Avifavir, which is the
first drug in the world to be registered for use in fighting the novel coronavirus infection. The highly effective drug will now be available not only in hospitals, but also for outpatient use. The provision of additional funding
from the state for the purchase of outpatient drugs for use in combating the coronavirus infection will also mean that people will continue to receive the drug free of charge not only in hospitals, but also through medical
prescriptions for use as a home treatment
Andrey Ivaschenko
No Avifavir® in your country? Ask us!
Our team
The team of our Foundation working to promote Avifavir in different countries.
Igor Berezovskyi
Russia
Vasil Krumov
Bulgaria-EU
Stoyan Dobrev
Germany
Thomas Rieger
EU — SADC